Enjoy complimentary customisation on priority with our Enterprise License!
The pulmonary arterial hypertension (PAH) drugs market size is estimated to grow by USD 2.08 billion at a CAGR of 6.62% between 2022 and 2027. Market growth relies on several factors, including the increasing incidence of PAH, the expanding elderly population, and the rising cardiovascular disease risk factors. These factors collectively drive market expansion, reflecting the escalating prevalence of PAH, which necessitates effective treatment solutions. Additionally, the growing geriatric population underscores the rising demand for healthcare services and treatments, including those for PAH. Moreover, the increasing risk factors for cardiovascular diseases highlight the need for advanced healthcare interventions, including those addressing PAH. Overall, these factors contribute to the market's growth by necessitating the development and adoption of innovative solutions to address the complex healthcare needs associated with PAH and related conditions.
It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
This market report extensively covers market segmentation by route of administration (oral, injectable, and inhalation), action mechanism (prostacyclin analogs, endothelin receptor antagonists (ERAS), phosphodiesterase (PDE) inhibitors, and soluble guanylate cyclase stimulators (SGCSS)), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The market share growth by the oral segment will be significant during the forecast period. Oral administration comprises tablets and suspensions, and tablets can be branched as film-coated tablets and extended-release tablets. Since the study of widespread animal and human efficacy and safety is not required in these formulations, the market segment is likely to witness growth during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The oral segment was valued at USD 2.93 billion in 2017. There are different oral drugs available for the treatment of PAH. The endothelin receptor antagonists (ERAs), bosentan and sitaxentan, and sildenafil are all used as oral medications to treat symptomatic, moderate-to-severe PAH. For instance, Ambrisentan is a brand-new oral ERA that selectively targets the ET(A) receptor and has a higher ET receptor affinity than bosentan. Ambrisentan (5 or 10 mg/day) is secure and efficient in placebo-controlled, randomized clinical trials (RCTs). Similarly, Bosentan, an oral dual ETA and ETB receptor antagonist increase exercise tolerance and cardiopulmonary hemodynamics in PAH patients. Thus, the growing use of oral drugs to treat PAH is expected to drive the growth of the oral administration segment in the market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America dominates the market and will hold the largest revenue share in 2022. A substantial portion of the market in focus is attributable to the developed healthcare systems in the US and Canada that make access to cutting-edge therapeutics easier. In addition, increasing awareness, high diagnostic rates, and favorable government initiatives are driving market growth in the region. Regional market expansion is also supported by a well-designed reward structure and the presence of key players. The need for advanced medical facilities to treat pulmonary arterial hypertension is driven by the rising prevalence and high diagnosis rates of infectious and chronic diseases in this region.
The market is driven by advancements in understanding the Cyclooxygenase (COX) pathway and the role of Soluble Guanylate Cyclase (sGC) and Nitric Oxide (NO) in treating the condition. PAH, a rare disease affecting the pulmonary arteries and capillaries, has seen an increase in treatment options, including orphan drugs. The market also focuses on addressing heart failures and congestive heart failure (CHF), improving the transportation of drugs, and advancing vaccine projects. Efforts in patient advocacy and early diagnosis initiatives have led to better patient outcomes, particularly important in managing PAH among patients with obesity. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing prevalence of PAH is the key factor driving the growth of the market. With the prevalence of PAH disease, the market is expanding. During the forecast period, the rising prevalence of PAH disease and associated hospitalizations for treatment are expected to increase the demand for the corresponding drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. As a result, blood pressure in the lungs increases, making it difficult for the heart to pump blood through narrowed arteries. A person's heart gradually loses its capacity to pump blood effectively throughout the body.
Women between the ages of 30 and 60 are most affected by PAH. According to the National Organization for Rare Disorders (NORD), women are three to five times more likely to develop PAH than men. Moreover, according to a study by the National Organization for Rare Disorders, around 500-1,000 new cases of PAH are recorded in the US every year, or 1-2 cases per billion people. Thus, the growing incidence of PAH is expected to drive the growth of the market during the forecast period.
Increasing awareness regarding PAH is the primary trend in the market. With the prevalence of PAH disease, the market is expanding. During the forecast period, the rising prevalence of PAH disease and associated hospitalizations for treatment are expected to increase the demand for the corresponding drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. As a result, blood pressure in the lungs increases, making it difficult for the heart to pump blood through narrowed arteries. There are numerous treatments on the market that aid in reducing the progression of diseases and enhancing the quality of life.
Additionally, the approval of a small number of potent medications and the existence of a promising pipeline are some key elements that will propel the growth of the market during the forecast period. Additionally, favorable government policies will help increase the demand for PAH treatments, which in turn will drive the growth of the market during the forecast period.
The shortage of healthcare professionals is a major challenge to the growth of the market. Our network of medical facilities, laboratories, and diagnostic centers spans the globe. The growing world population has increased the burden of running an effective healthcare system. The growth of the healthcare industry is hampered by several factors, such as high infrastructure, machinery and equipment costs, and lack of qualified staff. According to the WHO, there will be 12.9 billion fewer healthcare workers in the world by 2035 than in 2021.
Moreover, several factors, such as an aging workforce, a decline in the number of people entering the field, early retirements, inadequate training, and increased demands from an aging and growing population, all these factors will lead to a shortage of healthcare professionals. Thus, a shortage of healthcare professionals can become a major challenge to the growth of the market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aerami Therapeutics Holdings Inc.: The company offers pulmonary arterial hypertension drug solutions such as Orphan. Also, this segment focuses on developing inhaled therapies to treat severe respiratory and chronic diseases.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments.
The market is driven by the need to address Pulmonary Hypertension (PH), a condition that affects the pulmonary arterial hypertension drug market. Despite being a rare condition, PH can be fatal and requires specialized treatments, including SGC simulators targeting the NO sGC cGMP pathway. The market includes various drug classes, including generics and intravenous/subcutaneous therapies, to manage high blood pressure in the lungs. PAH often occurs in patients with underlying diseases such as lung cancer, chronic obstructive pulmonary disease, and congenital heart defects. Advances in drug delivery systems and regulatory approvals have improved diagnosis rates and reimbursement systems for PAH patients.
Furthermore, the market is influenced by various factors, including viral outbreaks that can impact the patient base and prompt patient advocacy efforts. It encompasses a range of drug classes and treatments due to the fatality associated with PAH and the need for orphan drug development. Generic alternatives play a role in managing costs and providing access to treatment. PAH is often diagnosed alongside lung-related disorders like interstitial lung disease and pulmonary fibrosis, as well as conditions such as coronary artery disease and lung blood clots. Advances like SGC stimulators and NO sGC signaling aim to improve outcomes, along with innovative delivery methods like the Remunity subcutaneous pump. Improvements in diagnosis rates and reimbursement systems have increased access to generic medications for PAH patients.
Market Scope |
|
Report Coverage |
Details |
Page number |
172 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.62% |
Market growth 2023-2027 |
USD 2.08 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.94 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 45% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Action Mechanism
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.